• TSH Biopharm is the sixth partner of Zhaoke on BRIMOCHOLTM PF in Asian Pacific and the Middle East

Zhaoke Ophthalmology Limited (“Zhaoke Ophthalmology”, “Zhaoke” or the “Company”, SEHK: 6622), a leading ophthalmic pharmaceutical company, is pleased to announce that the Company has entered into a strategic partnership with Taiwan-based TSH Biopharm Corporation Limited (“TSH”, TW: 8432) to jointly advance the clinical introduction and future commercialization of BRIMOCHOL™ PF in Taiwan Region. TSH Biopharm specializes in chronic diseases and precision medicine, providing safe and accessible care solutions.

Under the terms of the agreement, Zhaoke grants TSH, as its exclusive distributor, the right to register, import, promote, distribute, market, and sell BRIMOCHOL™ PF in Taiwan Region.

BRIMOCHOL™ PF is a potential treatment to correct the loss of near vision associated with presbyopia, which is the Company’s core asset licensed from Tenpoint Therapeutics, Ltd., a global, commercial-ready biotech company developing groundbreaking treatments to rejuvenate vision in the aging eye.

According to the 2021 National Health Interview Survey by Taiwan’s Health Promotion Administration, the proportion of people aged 45 and above with presbyopia has risen significantly, with a prevalence of 65.8% among those aged 65 and older, indicating that, alongside an aging population and changing visual habits, the demand for near vision is steadily increasing.

Prior to the collaboration with TSH, Zhaoke has already established commercial partnership with local distributors in South Korea, Australia/New Zealand, Thailand, Indonesia and the Middle East. In South Korea, the New Drug Application (“NDA”) on BRIMOCHOL™ PF has already been submitted and accepted by its regulatory authority.

In addition, in June 2025, Tenpoint Therapeutics, Ltd., Zhaoke’s partner and the developer of BRIMOCHOL™ PF, announced that the U.S. FDA accepted its New Drug Application (“NDA”) The FDA has set a Prescription Drug User Fee Act (“PDUFA”) date of 28 January 2026 for BRIMOCHOL™ PF.

Dr. Li Xiaoyi (Benjamin), Chairman of the Board, Executive Director and CEO of Zhaoke Ophthalmology, commented, “BRIMOCHOL™ PF represents a major milestone in our innovation pipeline for presbyopia treatment. We are excited to collaborate with TSH Biopharm, a highly respected leader in Taiwan’s specialty pharmaceutical market, to accelerate the clinical introduction and future market launch of this novel therapy. Together, we aim to enhance access to advanced vision-care solutions for the aging population in Taiwan Region.”

TSH Biopharm General Manager Sze Yuan Yang commented, “As Taiwan moves towards an increasingly aging society, the introduction of BRIMOCHOL™ PF not only enriches the self-paid presbyopia treatment landscape but also reinforces our commitment to bringing global innovations to improve visual health for the public. We sincerely appreciate the trust and partnership extended by Zhaoke Ophthalmology. Looking ahead, we are confident that our combined strengths will bring meaningful improvements to patient care and advance the development of innovative ophthalmic therapies in Taiwan Region.”

About BRIMOCHOL™ PF and BRIO-II Phase 3 Study
BRIMOCHOL™ PF is an investigational, preservative-free, once daily eyedrop to correct for the loss of near vision associated with aging. BRIO-II is a 3-arm, multicenter, randomized, double-masked, safety and efficacy study of BRIMOCHOL™ PF (carbachol/brimonidine tartrate fixed-dose combination) topical ophthalmic solution vs. carbachol monotherapy topical ophthalmic solution vs. a vehicle topical ophthalmic solution in subjects with emmetropic phakic or pseudophakic presbyopia (NCT05135286). The study enrolled 629 subjects across forty-seven sites in the United States.

About Presbyopia
Presbyopia is the gradual loss of near vision associated with aging, making it difficult to perform tasks like reading fine print. It typically begins in adults in their 40s and becomes almost universal by age 50. Presbyopia impacts billions of people globally with approximately 600 million adults affected in China, South Korea and Southeast Asia. In Australia, the total number of prevalence cases reached over 13.5 million in 2023, according to GlobalData. Reading glasses are the most common solution for near-vision correction; however, many people find glasses inconvenient or prefer not to wear them for aesthetic reasons. There are currently no approved presbyopia-correcting therapeutics in many countries across the Asia-Pacific region.

About TSH Biopharm Corporation Limited
Founded in 2010, TSH Biopharm Corporation Limited (TW-8432) is a Taiwan-based pharmaceutical company committed to patient-centric care and long-term disease management. The Company specializes in chronic therapeutic areas—cardiovascular, gastrointestinal, central nervous system, and ophthalmology—delivering safe, effective, and accessible solutions that address unmet needs in daily disease control and improve quality of life.

To meet evolving healthcare needs, TSH Biopharm has expanded beyond chronic-disease therapeutics into prevention and precision medicine, establishing an integrated framework that spans prevention, diagnosis, and treatment. Key initiatives—including probiotics, vaccines, and next-generation sequencing (NGS) testing—underscore the Company’s commitment to comprehensive, high-value healthcare.

Driven by its vision to enhance patient quality of life and serve as a preferred strategic partner for global biomedical innovation in Asia, TSH Biopharm continues to strengthen its chronic-care leadership, accelerate technology-driven innovation, and expand across emerging Asian markets. The Company upholds strong corporate responsibility and governance standards, aiming to create long-term, sustainable impact on public health.

For more information, please visit: https://www.tshbiopharm.com/


About Tenpoint Therapeutics
Tenpoint Therapeutics Ltd. is a global, commercial-ready biotechnology company developing groundbreaking treatments to rejuvenate vision in the aging eye. Its lead asset, BRIMOCHOL™ PF, is a novel pupil-modulating, investigational therapeutic designed to correct the loss of near vision associated with presbyopia, a condition that afflicts approximately two billion people globally. Tenpoint Therapeutics has completed two large Phase 3 pivotal trials (BRIO-I and BRIO-II) for BRIMOCHOL™ PF, has filed the New Drug Application (NDA) and has received a Prescription Drug User Fee Act (PDUFA) date from the U.S. Food and Drug Administration (FDA) of Jan. 28, 2026. Its pipeline includes paradigm-shifting treatments for ophthalmic indications with the greatest need and global market potential, including presbyopia, cataracts and geographic atrophy.

For more information, please visit: https://www.tenpointtherapeutics.com/

- End -